Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Video-assisted thoracic surgery : A global development].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2018
Same author

Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts.

Targeted oncology·2016
Same author

[Do thoracic surgery patients always need a postoperative chest X-ray?].

Zentralblatt fur Chirurgie·2014
Same author

Deficits 10-years after Achilles tendon repair.

International journal of sports medicine·2012
Same author

Novel therapies in non-small cell lung cancer.

Minerva chirurgica·2011
Same author

[Not Available].

Herzschrittmachertherapie & Elektrophysiologie·2009
Same journal

Unexpected evolution of COVID-19 in a heart transplant patient with multimorbidity recently submitted to thoracic surgery.

Minerva chirurgica·2020
Same journal

Ongoing clinical trials on axillary management.

Minerva chirurgica·2020
Same journal

Axillary management after neoadjuvant treatment.

Minerva chirurgica·2020
Same journal

Axillary observation alone versus sentinel node biopsy: past, present and future perspectives.

Minerva chirurgica·2020
Same journal

Patient flow for the management of ostomy patients.

Minerva chirurgica·2020
Same journal

The management of "fragile" and suspected COVID-19 surgical patients during pandemic: an Italian single-center experience.

Minerva chirurgica·2020
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Adjuvant therapy for lung cancer.

J Merk1, G Leschber

  • 1ELK Berlin Chest Hospital, Berlin, Germany. johannes.merk@elk-berlin.de

Minerva Chirurgica
|December 24, 2009
PubMed
Summary
This summary is machine-generated.

Adjuvant chemotherapy shows promise for stages II and III non-small cell lung cancer (NSCLC). Further research is needed to clarify its role in stage IB and for small cell lung cancer (SCLC) treatments.

Related Experiment Videos

Last Updated: Jun 17, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Medical Oncology

Background:

  • Lung cancer is a leading global cause of cancer mortality.
  • Early-stage diagnosis (IA-IIIA) occurs in only 30% of patients.
  • Complete surgical resection is optimal for non-small cell lung cancer (NSCLC), but recurrence rates necessitate adjuvant therapies.

Purpose of the Study:

  • To review the current status of adjuvant therapy in lung cancer.
  • To discuss future perspectives in lung cancer treatment.
  • To highlight the need for individualized treatment strategies.

Main Methods:

  • Review of clinical trials and meta-analyses on adjuvant chemotherapy for NSCLC.
  • Evaluation of evidence for adjuvant radiation and chemoradiotherapy.
  • Discussion of multimodality approaches for small cell lung cancer (SCLC).

Main Results:

  • Adjuvant chemotherapy is supported by evidence for stage II and III NSCLC.
  • The role of adjuvant chemotherapy in stage IB NSCLC remains controversial.
  • No current evidence supports routine adjuvant radiation or chemoradiotherapy post-resection.
  • Multimodality adjuvant therapy is feasible for early-stage SCLC, pending further trials.

Conclusions:

  • Adjuvant chemotherapy is established for advanced NSCLC.
  • Personalized treatment through prognostic and predictive markers is a future goal.
  • Further randomized trials are essential for optimizing SCLC adjuvant strategies.